Listening to friends, coworkers, and family conversations, you quickly realize that weekly weight loss shots have become part of the conversation in Madison the way gym memberships and juice cleanses used to be. Semaglutide and tirzepatide, the drugs behind Ozempic, Wegovy, Mounjaro, and Zepbound, aren’t a fad that’s going to fade by next spring. They’re backed by some of the largest weight-management trials ever run, and clinics across Dane County now offer them as part of a supervised weight loss program.
That said, there’s a lot of noise around these medications. Here’s what the research and the FDA actually say, and what it means if you’re considering treatment locally.
Obesity in Wisconsin
Wisconsin isn’t an outlier when it comes to weight, but it isn’t doing great either. Roughly two-thirds of adults in the state carry excess weight, and Madison itself sits at about 32% adult obesity, according to County Health Rankings data from Dane County health records. What’s interesting locally is how uneven that number is. Zip codes right around the isthmus and near campus report some of the lowest obesity rates in the state, while zip codes just a few miles out can run twice as high. That gap says less about willpower and more about access: to specialists, to time, to walkable neighborhoods, to food that doesn’t come from a gas station on the way home from a second shift.
For a lot of people, six months of diet apps and half-marathon training plans just haven’t moved the number the way they hoped. That’s the gap these medications are designed to fill, not replace healthy habits, but make them easier to sustain.
What’s actually in the syringe
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut already produces after eating, one that slows down how fast your stomach empties and signals your brain that you’re full. Tirzepatide does something similar but hits two hormone receptors instead of one, GLP-1 and GIP, which is part of why it tends to outperform semaglutide in head-to-head comparisons.
That comparison isn’t theoretical. In the SURMOUNT-5 trial, published in the New England Journal of Medicine, patients on tirzepatide (Zepbound) lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% for patients on semaglutide (Wegovy). In real terms, that’s roughly 50 pounds versus 33 pounds for the average participant. Nearly half of the tirzepatide group lost 20% or more of their starting weight. Neither drug works like magic, and neither works without the diet and activity changes that go alongside it, but the numbers are real and they’re reproducible.
One distinction that gets glossed over online: Ozempic and Mounjaro are FDA-approved specifically for type 2 diabetes. Wegovy and Zepbound are the versions of those same molecules that went through separate clinical trials and received FDA approval for chronic weight management.
Why sourcing matters right now, more than it did two years ago
Here’s something that’s changed meaningfully since these drugs first went mainstream. During the nationwide shortage, a wave of compounding pharmacies stepped in to produce lower-cost versions of semaglutide and tirzepatide, and telehealth companies marketed them aggressively. That era is closing. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, and by early 2026 the agency had moved to shut the door on compounded versions altogether, proposing in April to remove semaglutide, tirzepatide, and liraglutide from the list of drugs outsourcing facilities are allowed to compound from bulk ingredients. In February 2026, FDA sent warning letters to roughly thirty telehealth operators over misleading marketing of compounded GLP-1 products, following hundreds of adverse event reports tied to dosing errors from multidose vials.
None of that is meant as an alarm bell about compounding as a category. It’s a reason to ask direct questions before you start treatment anywhere: is this FDA-approved medication from a licensed pharmacy, who’s actually reviewing your labs, and who do you call at 9pm if you have a bad reaction. A Madison-based practice where you can walk in for bloodwork and sit across from the same provider at your follow-up visit answers those questions a lot more easily than a website that ships a vial to your door.
What treatment actually looks like
The injections themselves are simple: a once-weekly shot under the skin of the stomach, thigh, or upper arm, rotated week to week, using either a prefilled pen or a vial and syringe depending on what’s prescribed. Storage matters more than people expect. Most formulations need refrigeration, with a limited window at room temperature before they need to be discarded, so a night in a hot car or a forgotten cooler can ruin a dose.
Dosing starts low, usually 2.5 mg of tirzepatide or the lowest semaglutide dose, and increases gradually over weeks, which is part of why the GI side effects tend to be worst early on and fade as the dose stabilizes. Missing a dose isn’t a crisis; there are clear rules for when to take it late versus skip it and wait for the next one, and any provider prescribing these should walk you through that before you leave with your first prescription.
The honest bottom line
For the right patient, someone with obesity or weight-related health complications who’s already tried the standard playbook, these medications produce results that diet and exercise alone rarely match. For Madison specifically, where winters make outdoor activity harder for a solid third of the year and where the obesity gap between neighborhoods is wider than the citywide average suggests, a medically supervised program can close a gap that willpower alone hasn’t.
They’re not a shortcut, and they’re not risk-free. They’re a tool, one that works best when a real clinician is checking your labs, adjusting your dose, and staying reachable if something feels off. If you’re weighing whether weekly injections make sense for you, that conversation is worth having with a licensed provider in person, not just a checkbox on an intake form.
This article is for informational purposes only and isn’t a substitute for individualized medical advice. Anyone considering semaglutide or tirzepatide treatment should consult a licensed healthcare provider to review their full medical history and determine whether it’s appropriate for them.
Sources:
- Tirzepatide (subcutaneous route) — Mayo Clinic
- Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in NEJM — Eli Lilly and Company
- Wegovy vs. Ozempic: The truth about these weight-loss drugs — UCHealth Today
- Adult Obesity, County Health Rankings & Roadmaps (Dane County / Madison)
- Explore Obesity in Wisconsin — America’s Health Rankings
- FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize — U.S. Food and Drug Administration
- FDA Moves to Permanently Close the Door on Compounded GLP-1s — Pharmacy Times
- Weekly Weight Loss Injections — Lasting Skin Solutions, Madison WI
